KPTI - Karyopharm Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

168.3M

Cash

236.8M

Avg Qtr Burn

-24.96M

Short % of Float

16.92%

Insider Ownership

5.01%

Institutional Own.

73.63%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
XPOVIO (Selinexor) (XPO1 inhibitor) Details Multiple myeloma, Diffuse large B cell lymphoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) + ruxolitinib Details Myelofibrosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) Details Cancer, Endometrial cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eltanexor Details Colorectal cancer , Prostate cancer, Multiple myeloma, Myelodysplastic syndrome	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) Details Glioblastoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) (in combination with rituximab-gemcitabine-dexamethasone-platinum (R-GDP)) Details Diffuse large B cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KPT-9274 (PAK4 and NAMPT inhibitor) Details Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) Details Rare diseases, Liposarcoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XPOVIO (Selinexor) (XPO1 inhibitor) Details Multiple myeloma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.